MGC Pharmaceutical receives Health Canada approval
Published 30-MAY-2016 11:33 A.M.
|
1 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Following on from last week’s news that MGC Pharmaceutical (ASX:MXC) had received FDA approval to sell and distribute its CBD-based cosmetic products across the US, comes the news that Health Canada has also given MGC Pharmaceuticals regulatory approval.
Health Canada approval enables MGC Pharmaceuticals to pursue distribution and sales agreements in a market estimated to be $US1.9 billion.
MGC Pharmaceuticals is currently in negotiations on distribution agreements in Canada to facilitate sales into this key market.
The Canadian market is a leader in the global medicinal field, and with pharmaceutical ambitions as well as a retail agenda, approval in this region is critical to MGC Pharmaceutical’s long-term business plan.
“MGC Pharmaceuticals has moved forward with its commercialisation strategy for its CBD cosmetics range at a rapid pace, delivering key regulatory approvals, distribution agreements and commencing sales in recent months,” said MGC Pharmaceuticals co-founder and managing director Nativ Segev.
“Our approval from Health Canada is another strong step forward, enabling us to expand our geographic sales reach for the products into Canada, which has a very progressive attitude and legislation for medicinal cannabis and related product markets.
MGC Pharmaceuticals has now managed to gain approval from the FDA in the US, the European Commission’s Cosmetic products Notification Portal (CPNP) for its cosmetics product line.
The company is also awaiting approval in Australia from the Australian Therapeutic Good Administration (TGA).
It is expected the TGA will hand down its decision shortly. If favourable, MGC Pharmaceuticals would be able to sell the cosmetics product line to Australian consumers and MXC’s shareholders.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
